V3V Share Price Performance
€5.25
1.11 (26.81%)
Price €5.25
Share Pricen/a
Is FamiCord (ETR:V3V) Using Too Much Debt?
Sep 23
FamiCord AG Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
V3V Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
FamiCord AG Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.56
- 28.41%
- -11.15%
- 65.3%
About V3V
- Founded
- 1997
- Employees
- 766
- CEO
- WebsiteView website
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.
